Skip to content

Platelet-rich Plasma(PRP) Injection in ED

A Prospective Trial of Autologous Platelet-rich Plasma Injection in Erectile Dysfunction Treatment

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05241964
Enrollment
30
Registered
2022-02-16
Start date
2021-03-22
Completion date
2022-11-29
Last updated
2022-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erectile Dysfunction, PRP

Brief summary

RPR contains rich-in growth factors and has the properties of helping tissue regeneration and nerve repair. In theory, it is possibility of curing ED.

Detailed description

There are many reasons of erectile dysfunction(ED). If left untreated, there is a major impact on relationships, self-esteem, and overall health. RPR contains rich-in growth factors and has the properties of helping tissue regeneration and nerve repair. Its mechanism is to promote the regeneration of blood vessels in the cavernous body of the penis, increase blood circulation, and then help erection, increase penile stiffness and improve the phenomenon of premature ejaculation. The main purpose of this study is to study the safety and effectiveness of PRP injection for the treatment of ED.

Interventions

BIOLOGICALPRP

4\ 6ml autologous platelet rich plasma injection every 14±2 days for a total of 5 injections.

Sponsors

National Taiwan University Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
20 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Male * Between 20 and 70 years old * Sexual dysfunction exists for at least 6 months * IIEF-5 score 8-2 * Sign an informed consent form

Exclusion criteria

* Ever radical prostatectomy or extensive pelvic surgery * Radiation therapy to the pelvic area within 12 months before recruiting * Cancer * Nervous system diseases that affect erectile function * Have any blood disease * History of coronary artery disease

Design outcomes

Primary

MeasureTime frameDescription
International Index of Erectile Function(IIEF-5)Change from 0 week at 4,8,12,24,48 weeksThe possible scores for the IIEF-5 range from 5 to 25, and ED was classified into five categories based on the scores: severe (5-7), moderate (8-11), mild (12-21), and no ED (22-25).

Secondary

MeasureTime frameDescription
Erection Hardness Score(EHS)Change from 0 week at 4,8,12,24,48 weeksEHS can be a helpful tool to evaluate ED - a man's inability to get or maintain an erection firm enough for sex. To select one of the following options: 0 Penis does not enlarge 1. Penis is larger, but not hard 2. Penis is hard, but not hard enough for penetration 3. Penis is hard enough for penetration, but not completely hard 4. Penis is completely hard and fully rigid
Duplex - Peak systolic velocity(PSV)0,16 weeksTo assess penile hemodynamics - Penile arterial blood velocity record (cm/s)
Duplex - Resistance index(RI)0,16 weeksTo assess penile hemodynamics - Penile vascular resistance Index

Countries

Taiwan

Contacts

Primary ContactI-Ni Chiang, MD
inichiang@gmail.com+886919077219

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026